Finance entity
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Novartis AG, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Novartis AG, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window. The 8 average consequence score is above the beat benchmark of 6.5 in the same window. We currently track 1 Finance story that mention SNV4818, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 72 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SNV4818. Shared-story counts are live from our verified record — not editorial picks.
Novartis AG has reached an agreement to acquire an experimental breast cancer treatment from Synnovation Therapeutics for a total consideration of up to $3 billion. The deal centers on SNV4818, a promising oncology candidate designed to strengthen Novartis's position in the highly competitive breast cancer market.
SNV4818 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
